journal
Journals Journal of the National Compre...

Journal of the National Comprehensive Cancer Network : JNCCN

https://read.qxmd.com/read/38503055/update-on-the-sentinel-node-procedure-in-vulvar-cancer
#21
REVIEW
Willemijn L van der Kolk, Joost Bart, Ate J G van der Zee, Maaike H M Oonk
Early-stage vulvar cancer is managed by a local excision of the primary tumor and, if indicated, a sentinel node (SN) biopsy to assess the need for further groin treatment. With the SN procedure, many patients can be treated less radically and will experience less complications and morbidity compared with an inguinofemoral lymphadenectomy (IFL). Still, the SN procedure can be further optimized. Different tracers for detecting the SN are being investigated, aiming to optimize detection rates and decrease the burden of the procedure and short-term complications...
March 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38503054/changes-on-the-horizon
#22
JOURNAL ARTICLE
Margaret Tempero
No abstract text is available yet for this article.
March 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38503048/hope-for-a-future-free-of-unconscious-biases-and-racial-anxiety-in-cancer-care
#23
JOURNAL ARTICLE
Elliot A Asare, Oluwadamilola M Fayanju
No abstract text is available yet for this article.
March 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38503043/mesothelioma-pleural-version-1-2024
#24
JOURNAL ARTICLE
James Stevenson, David S Ettinger, Douglas E Wood, Dara L Aisner, Wallace Akerley, Jessica R Bauman, Ankit Bharat, Debora S Bruno, Joe Y Chang, Lucian R Chirieac, Malcolm DeCamp, Aakash Desai, Thomas J Dilling, Jonathan Dowell, Gregory A Durm, Marina C Garassino, Scott Gettinger, Travis E Grotz, Matthew A Gubens, Rudy P Lackner, Michael Lanuti, Jules Lin, Billy W Loo, Christine M Lovly, Fabien Maldonado, Erminia Massarelli, Daniel Morgensztern, Trey C Mullikin, Thomas Ng, Gregory A Otterson, Dawn Owen, Sandip P Patel, Tejas Patil, Patricio M Polanco, Gregory J Riely, Jonathan Riess, Theresa A Shapiro, Aditi P Singh, Alda Tam, Tawee Tanvetyanon, Jane Yanagawa, Stephen C Yang, Edwin Yau, Kristina Gregory, Lisa Hang
Mesothelioma is a rare cancer that originates from the mesothelial surfaces of the pleura and other sites, and is estimated to occur in approximately 3,500 people in the United States annually. Pleural mesothelioma is the most common type and represents approximately 85% of these cases. The NCCN Guidelines for Mesothelioma: Pleural provide recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with pleural mesothelioma. These NCCN Guidelines Insights highlight significant updates to the NCCN Guidelines for Mesothelioma: Pleural, including revised guidance on disease classification and systemic therapy options...
March 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38394783/group-coping-intervention-in-patients-with-chronic-graft-versus-host-disease-a-pilot-randomized-clinical-trial
#25
JOURNAL ARTICLE
Ashley M Nelson, Daniel Yang, Annemarie D Jagielo, Jennifer D'Alotto, Cathleen Poliquin, Dustin J Rabideau, Katherine G Cronin, Richard A Newcomb, Yi-Bin Chen, Zachariah DeFilipp, Joseph A Greer, Areej El-Jawahri, Lara Traeger
BACKGROUND: More than half the long-term survivors of allogeneic hematopoietic cell transplantation develop chronic graft-versus-host disease (GVHD), a debilitating inflammatory syndrome. Supportive interventions to assist survivors in coping with chronic GVHD are critically needed. PATIENTS AND METHODS: We conducted a pilot randomized clinical trial of a multidisciplinary group intervention (Horizons Program; n=39) versus minimally enhanced usual care (n=41) for patients with moderate or severe chronic GVHD...
February 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38394782/association-between-alcohol-use-disorder-and-hospital-readmission-rates-and-outcomes-in-cancer-survivors-a-population-cohort-study
#26
JOURNAL ARTICLE
Jyun-Heng Lai, Sola Han, Chanhyun Park, Anton L V Avanceña
BACKGROUND: Alcohol use disorder (AUD) is the most common substance use disorder and is characterized by heavy alcohol use and the inability to control drinking. This study sought to compare the rate, timing, length, and total costs of hospital readmissions among cancer survivors with and without AUD. METHODS: We used the Nationwide Readmissions Database in 2017 and 2018 in this cohort study. Cancer survivors with an AUD diagnosis during their index hospitalization were included in the exposure group...
February 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38394781/nccn-guidelines%C3%A2-insights-kidney-cancer-version-2-2024
#27
JOURNAL ARTICLE
Robert J Motzer, Eric Jonasch, Neeraj Agarwal, Ajjai Alva, Hilary Bagshaw, Michael Baine, Kathryn Beckermann, Maria I Carlo, Toni K Choueiri, Brian A Costello, Ithaar H Derweesh, Arpita Desai, Yasser Ged, Saby George, John L Gore, Andrew Gunn, Naomi Haas, Michael Johnson, Payal Kapur, Jennifer King, Christos Kyriakopoulos, Elaine T Lam, Primo N Lara, Clayton Lau, Bryan Lewis, David C Madoff, Brandon Manley, M Dror Michaelson, Amir Mortazavi, Lee Ponsky, Sundhar Ramalingam, Brian Shuch, Zachary L Smith, Jeffrey Sosman, Randy Sweis, Matthew Zibelman, Ryan Schonfeld, MaryElizabeth Stein, Lisa A Gurski
The NCCN Guidelines for Kidney Cancer provide multidisciplinary recommendations for diagnostic workup, staging, and treatment of patients with renal cell carcinoma (RCC). These NCCN Guidelines Insights focus on the systemic therapy options for patients with advanced RCC and summarize the new clinical data evaluated by the NCCN panel for the recommended therapies in Version 2.2024 of the NCCN Guidelines for Kidney Cancer.
February 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38394779/an-infant-type-hemispheric-glioma-with-sox5-alk-a-novel-fusion
#28
JOURNAL ARTICLE
Chia Chin Tsai, Man-Hsu Huang, Chia-Lang Fang, Kevin Li-Chun Hsieh, Tsung-Han Hsieh, Wan-Ling Ho, Hsi Chang, Min-Lan Tsai, Yu-Chien Kao, James S Miser, Tai-Tong Wong, Min-Yu Su, Yen-Lin Liu
Infant-type hemispheric glioma (IHG) is a rare pediatric brain tumor with variable response to chemotherapy and radiotherapy. Molecular insights into IHG can be useful in identifying potentially active targeted therapy. A male fetus was found to have congenital hydrocephalus at the gestational age of 37 weeks. Fetal MRI showed a 2.6 × 2.0-cm tumor located at the frontal horn of the left lateral ventricle, involving the left basal nuclei and thalamus. Tumor biopsy at the age of 2 days revealed an IHG consisting of spindle tumor cells with strong expression of GFAP and ALK...
February 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38394778/patient-centered-decision-making-in-metastatic-breast-cancer-care-delivery-a-call-to-action
#29
JOURNAL ARTICLE
Gabrielle B Rocque, Manali I Patel, Lauren P Wallner, Stacy C Bailey, Rebekkah Schear, Christine M Gunn, Jamil Rivers, Rozanne Wilson, Emily C Freeman, Trudy L Buckingham, Suepattra G May, Arif H Kamal
No abstract text is available yet for this article.
February 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38394774/beyond-bcr-abl1-the-role-of-genomic-analyses-in-the-management-of-cml
#30
REVIEW
Susan Branford, Adelina Fernandes, NurHezrin Shahrin, Muneeza Maqsood, Naranie Shanmuganathan, Carol Wadham
Chronic myeloid leukemia (CML) is a model of genomically based diagnosis and management where BCR::ABL1 is successfully targeted by tyrosine kinase inhibitor (TKI) therapy in most patients. The dynamics of BCR::ABL1 transcript decline during therapy is a dependable biomarker of response, relapse, and drug resistance. Missense mutations acquired within the BCR::ABL1 kinase domain that disrupt TKI binding can evolve during therapy and are frequently detected in patients for whom TKI treatment fails. Importantly, specific BCR::ABL1 missense mutations are targetable alterations and direct therapeutic decisions based on the individual mutant TKI sensitivity profile...
February 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38394773/navigating-the-management-of-chronic-phase-cml-in-the-era-of-generic-bcr-abl1-tyrosine-kinase-inhibitors
#31
REVIEW
Fadi G Haddad, Hagop Kantarjian
Over the past several years, advances in research, treatment, and market dynamics have impacted treatment strategies in chronic myeloid leukemia in chronic phase (CML-CP). They include the broader availability of cost-effective generic imatinib, and soon other generic second-generation tyrosine kinase inhibitors (TKIs). Access to affordable generics means that all patients with CML-CP should have access to safe and highly effective lifelong therapies. When overall survival is the treatment endpoint, imatinib provides a good treatment value...
February 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38394772/disparities-in-survival-and-nccn-guideline-concordant-care-in-patients-with-extremity-soft-tissue-sarcoma
#32
JOURNAL ARTICLE
Hayley M Dunlop, Bence Bende, Samantha M Ruff, Alex Kim, James L Fisher, Valerie P Grignol, Carlo M Contreras, Samilia Obeng-Gyasi, David J Konieczkowski, Timothy M Pawlik, Raphael E Pollock, Joal D Beane
BACKGROUND: Based on the NCCN Guidelines for Soft Tissue Sarcoma (STS), treatment of extremity STS (ESTS) includes radiation therapy (RT) and surgical resection for tumors that are high-grade and >5 cm. ​​The aim of this study was to describe the association between neighborhood socioeconomic status (nSES), concordance with NCCN Guidelines recommendations, and outcomes in patients with ESTS. METHODS: Patients with ESTS diagnosed from 2006 through 2018 were identified in SEER registries...
February 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38394770/chronic-myeloid-leukemia-version-2-2024-nccn-clinical-practice-guidelines-in-oncology
#33
JOURNAL ARTICLE
Neil P Shah, Ravi Bhatia, Jessica K Altman, Maria Amaya, Kebede H Begna, Ellin Berman, Onyee Chan, Joan Clements, Robert H Collins, Peter T Curtin, Daniel J DeAngelo, Michael Drazer, Lori Maness, Leland Metheny, Sanjay Mohan, Joseph O Moore, Vivian Oehler, Keith Pratz, Iskra Pusic, Michal G Rose, William Shomali, B Douglas Smith, Michael Styler, Moshe Talpaz, Tiffany N Tanaka, Srinivas Tantravahi, James Thompson, Steven Tsai, Jennifer Vaughn, Jeanna Welborn, David T Yang, Hema Sundar, Kristina Gregory
Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome resulting from a reciprocal translocation between chromosomes 9 and 22 [t9;22] that gives rise to a BCR::ABL1 fusion gene. CML occurs in 3 different phases (chronic, accelerated, and blast phase) and is usually diagnosed in the chronic phase in developed countries. Tyrosine kinase inhibitor (TKI) therapy is a highly effective treatment option for patients with chronic phase-CML. The primary goal of TKI therapy in patients with chronic phase-CML is to prevent disease progression to accelerated phase-CML or blast phase-CML...
February 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38394769/guest-editorial-reflections-of-a-new-chief-executive-officer
#34
JOURNAL ARTICLE
Crystal S Denlinger
No abstract text is available yet for this article.
February 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38394768/value-of-size-and-malignant-features-of-lateral-lymph-nodes-in-risk-stratification-at-lateral-local-recurrence-of-rectal-cancer-a-national-cohort-study
#35
JOURNAL ARTICLE
Eline G M van Geffen, Tania C Sluckin, Sanne-Marije J A Hazen, Karin Horsthuis, Regina G H Beets-Tan, Susan van Dieren, Corrie A M Marijnen, Pieter J Tanis, Miranda Kusters
BACKGROUND: Patients with rectal cancer who have enlarged lateral lymph nodes (LLNs) have an increased risk of lateral local recurrence (LLR). However, little is known about prognostic implications of malignant features (internal heterogeneity, irregular margins, loss of fatty hilum, and round shape) on MRI and number of enlarged LLNs, in addition to LLN size. METHODS: Of the 3,057 patients with rectal cancer included in this national, retrospective, cross-sectional cohort study, 284 with a cT3-4 tumor located ≤8 cm from the anorectal junction who received neoadjuvant treatment and who had visible LLNs on MRI were selected...
February 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38190802/associations-among-optimal-lung-cancer-treatment-clinical-outcomes-and-health-care-utilization-in-patients-who-underwent-comprehensive-genomic-profiling
#36
JOURNAL ARTICLE
Adam C Powell, Elifnur Yay Donderici, Nicole J Zhang, Shaun P Forbes, Julie Wiedower, Amy C McNeal, Mark D Hiatt
BACKGROUND: Although immune checkpoint inhibitor immunotherapies are contraindicated as first-line treatment of advanced non-small cell lung cancer (NSCLC) in patients with ALK rearrangement and EGFR mutation, many receive them. The purpose of this study was to examine the association between optimal first-line treatment in this population and clinical outcomes. METHODS: Claims and genomic data from patients with advanced or metastatic NSCLC were extracted from a nationally representative GuardantINFORM dataset...
January 8, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38244274/nccn-guidelines%C3%A2-insights-merkel-cell-carcinoma-version-1-2024
#37
JOURNAL ARTICLE
Chrysalyne D Schmults, Rachel Blitzblau, Sumaira Z Aasi, Murad Alam, Arya Amini, Kristin Bibee, Diana Bolotin, Jeremy Bordeaux, Pei-Ling Chen, Carlo M Contreras, Dominick DiMaio, Jessica M Donigan, Jeffrey M Farma, Karthik Ghosh, Kelly Harms, Alan L Ho, John Nicholas Lukens, Susan Manber, Lawrence Mark, Theresa Medina, Kishwer S Nehal, Paul Nghiem, Kelly Olino, Soo Park, Tejesh Patel, Igor Puzanov, Jason Rich, Aleksandar Sekulic, Ashok R Shaha, Divya Srivastava, Valencia Thomas, Courtney Tomblinson, Puja Venkat, Yaohui Gloria Xu, Siegrid Yu, Mehran Yusuf, Beth McCullough, Sara Espinosa
The NCCN Guidelines for Merkel Cell Carcinoma (MCC) provide recommendations for diagnostic workup, clinical stage, and treatment options for patients. The panel meets annually to discuss updates to the guidelines based on comments from expert review from panel members, institutional review, as well as submissions from within NCCN and external organizations. These NCCN Guidelines Insights focus on the introduction of a new page for locally advanced disease in the setting of clinical node negative status, entitled "Clinical N0 Disease, Locally Advanced MCC...
January 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38244272/waldenstr%C3%A3-m-macroglobulinemia-lymphoplasmacytic-lymphoma-version-2-2024-nccn-clinical-practice-guidelines-in-oncology
#38
JOURNAL ARTICLE
Shaji K Kumar, Natalie S Callander, Kehinde Adekola, Larry D Anderson, Muhamed Baljevic, Rachid Baz, Erica Campagnaro, Jorge J Castillo, Caitlin Costello, Christopher D'Angelo, Benjamin Derman, Srinivas Devarakonda, Noura Elsedawy, Alfred Garfall, Kelly Godby, Jens Hillengass, Leona Holmberg, Myo Htut, Carol Ann Huff, Malin Hultcrantz, Yubin Kang, Sarah Larson, Hans Lee, Michaela Liedtke, Thomas Martin, James Omel, Timothy Robinson, Aaron Rosenberg, Douglas Sborov, Mark A Schroeder, Daniel Sherbenou, Attaya Suvannasankha, Jason Valent, Asya Nina Varshavsky-Yanovsky, Jenna Snedeker, Rashmi Kumar
The treatment of Waldenström macroglobulinemia/lymphoplasmacytic lymphoma (WM/LPL) has evolved to include several new options. The NCCN Guidelines for WM/LPL provide a framework on which to base decisions regarding diagnosis, treatment, assessment of response to treatment, and follow-up of both newly diagnosed and previously treated WM/LPL.
January 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38244270/a-new-beginning
#39
JOURNAL ARTICLE
Margaret Tempero
No abstract text is available yet for this article.
January 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38154251/mode-of-detection-of-second-breast-cancers-in-patients-undergoing-surveillance-after-treatment-of-ductal-carcinoma-in-situ
#40
JOURNAL ARTICLE
Bethany T Waites, Liisa Lyon, Gillian Kuehner, Patience Odele, Laurel A Habel, Raymond Liu
BACKGROUND: For patients undergoing posttreatment surveillance after ductal carcinoma in situ (DCIS), the NCCN Guidelines for Breast Cancer recommend annual breast imaging and physical examination every 6 to 12 months for 5 years, and then annually. The aim of our study was to evaluate the modes of detection (imaging, patient reported, or physical examination) of second cancers in a cohort of patients undergoing surveillance after primary DCIS treatment to better inform surveillance recommendations...
December 28, 2023: Journal of the National Comprehensive Cancer Network: JNCCN
journal
journal
40348
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.